

















Selected references

Recent Capital Markets and Public M&A Mandates

 <p>Adviser to Oncopeptides in connection with a directed share issue</p> <p>2019</p>	 <p>Adviser to Azelio in connection with its capital raising and listing on Nasdaq First North</p> <p>2018</p>	 <p>Adviser to Xspray Pharma in connection with a directed share issue</p> <p>2018</p>	 <p>Adviser to Biotage in connection with its acquisition of PhyNexus</p> <p>2018</p>
 <p>Adviser to Vicore Pharma in connection with a directed share issue</p> <p>2018</p>	 <p>Adviser to Vostok New Ventures in connection with its investment in Voi</p> <p>2018</p>	 <p>Adviser to Equinor in connection with its investment in Medfield Diagnostics</p> <p>2018</p>	 <p>Adviser to Hansa Medical in connection with a directed share issue</p> <p>2018</p>
 <p>Adviser to Investor and the Knut and Alice Wallenberg Foundation in connection with Saab's right offering</p> <p>2018</p>	 <p>Adviser to William Hill in connection with the public offer to the shareholders in Mr. Green</p> <p>2018</p>	 <p>Adviser to Autoliv and Veoneer in connection with the spin-off and listing of Veoneer on NYSE and Nasdaq Stockholm</p> <p>2018</p>	 <p>Adviser to Ambea on its acquisition of Aleris</p> <p>2018</p>
 <p>Adviser to Klöver in connection with the public offer to the shareholders in Agora</p> <p>2018</p>	 <p>Adviser to Tele2 in connection with the merger with Com Hem</p> <p>2018</p>	 <p>Adviser to Cantargia in connection with its main market listing on Nasdaq Stockholm</p> <p>2018</p>	 <p>Adviser to IBT on its Nasdaq Stockholm main market listing</p> <p>2018</p>